Tibet Cheezheng Tibetan Medicine Co., Ltd.
Simbolis: 002287.SZ
SHZ
22.21
CNYRinkos kaina šiandien
20.1008
P/E santykis
0.0000
PEG koeficientas
11.78B
MRK kapitalizacija
- 0.02%
DIV pajamingumas
Tibet Cheezheng Tibetan Medicine Co., Ltd. (002287-SZ) Finansinės ataskaitos
Balansas
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 10005.55 | 2366.5 | 1976.9 | 1850.6 | ||||||||||||||||||
balance-sheet.row.short-term-investments | 8430.88 | 1963 | 1539.3 | 1184 | ||||||||||||||||||
balance-sheet.row.net-receivables | 3258.11 | 663.5 | 841.2 | 629.6 | ||||||||||||||||||
balance-sheet.row.inventory | 642.83 | 156.3 | 127.8 | 118.5 | ||||||||||||||||||
balance-sheet.row.other-current-assets | 87.71 | 8 | 246.6 | 337.7 | ||||||||||||||||||
balance-sheet.row.total-current-assets | 14048.36 | 3194.4 | 3192.4 | 2936.4 | ||||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 5861.27 | 1651.6 | 1144.4 | 821.4 | ||||||||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.intangible-assets | 1413.28 | 351.6 | 374.8 | 399.3 | ||||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 1413.28 | 351.6 | 374.8 | 399.3 | ||||||||||||||||||
balance-sheet.row.long-term-investments | -561.9 | 1056.5 | -423.1 | -42.4 | ||||||||||||||||||
balance-sheet.row.tax-assets | 139.57 | 39.4 | 29.1 | 26.7 | ||||||||||||||||||
balance-sheet.row.other-non-current-assets | 5055.39 | 4.9 | 1568.9 | 1426.4 | ||||||||||||||||||
balance-sheet.row.total-non-current-assets | 11907.61 | 3104.1 | 2694.2 | 2631.4 | ||||||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.total-assets | 25955.97 | 6298.5 | 5886.6 | 5567.8 | ||||||||||||||||||
balance-sheet.row.account-payables | 744.05 | 255.6 | 93.5 | 184 | ||||||||||||||||||
balance-sheet.row.short-term-debt | 3466.68 | 478 | 762.3 | 610.8 | ||||||||||||||||||
balance-sheet.row.tax-payables | 237.12 | 55.6 | 61.9 | 37.7 | ||||||||||||||||||
balance-sheet.row.long-term-debt-total | 4253.1 | 1061.3 | 934.4 | 841.4 | ||||||||||||||||||
Deferred Revenue Non Current | 754.86 | 191.3 | 167 | 154.7 | ||||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 127.94 | - | - | - | ||||||||||||||||||
balance-sheet.row.other-current-liab | 460.38 | 437.7 | 402.2 | 4.6 | ||||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 4959.4 | 1089.2 | 1138.9 | 1039.4 | ||||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.capital-lease-obligations | 21.98 | 7 | 4.9 | 4.9 | ||||||||||||||||||
balance-sheet.row.total-liab | 11067.61 | 2334.4 | 2499 | 2347.4 | ||||||||||||||||||
balance-sheet.row.preferred-stock | 471.98 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.common-stock | 2120.75 | 530.2 | 530.2 | 530.3 | ||||||||||||||||||
balance-sheet.row.retained-earnings | 8154.57 | 2104.1 | 1784.8 | 1667 | ||||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 2375.97 | 631.3 | 566.4 | 507.4 | ||||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 1369.17 | 454.7 | 454.6 | 464.3 | ||||||||||||||||||
balance-sheet.row.total-stockholders-equity | 14492.44 | 3720.3 | 3336 | 3169 | ||||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 25955.97 | 6298.5 | 5886.6 | 5567.8 | ||||||||||||||||||
balance-sheet.row.minority-interest | 202.02 | 49.8 | 51.6 | 51.4 | ||||||||||||||||||
balance-sheet.row.total-equity | 14694.46 | 3770.1 | 3387.7 | 3220.4 | ||||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 25955.97 | - | - | - | ||||||||||||||||||
Total Investments | 5660.63 | 3019.6 | 1116.2 | 1141.6 | ||||||||||||||||||
balance-sheet.row.total-debt | 7726.78 | 1546.3 | 1696.7 | 1452.2 | ||||||||||||||||||
balance-sheet.row.net-debt | 6152.1 | 1142.9 | 1259.1 | 785.6 |
Pinigų srautų ataskaita
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 585.9 | 581.2 | 469.5 | 710.8 | ||||||||||||||||||
cash-flows.row.depreciation-and-amortization | 7.51 | 95.8 | 83.2 | 65.8 | ||||||||||||||||||
cash-flows.row.deferred-income-tax | -17.2 | -24.3 | -8.3 | 38.8 | ||||||||||||||||||
cash-flows.row.stock-based-compensation | 0.87 | -168.3 | 3.6 | 4.9 | ||||||||||||||||||
cash-flows.row.change-in-working-capital | 38 | 47.8 | -374.7 | 521.1 | ||||||||||||||||||
cash-flows.row.account-receivables | 41.95 | 42 | -209.3 | 369.7 | ||||||||||||||||||
cash-flows.row.inventory | -28.46 | -28.5 | -10.6 | -24 | ||||||||||||||||||
cash-flows.row.account-payables | 0 | 9.8 | -146.4 | 136.6 | ||||||||||||||||||
cash-flows.row.other-working-capital | 24.51 | 24.5 | -8.3 | 38.8 | ||||||||||||||||||
cash-flows.row.other-non-cash-items | 320.18 | 439.6 | 112.5 | -306.5 | ||||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 934.39 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -254.94 | -234.8 | -272.4 | -125.6 | ||||||||||||||||||
cash-flows.row.acquisitions-net | -0.56 | -0.6 | -3.8 | -61.1 | ||||||||||||||||||
cash-flows.row.purchases-of-investments | -1450 | -1492.4 | -1418 | -3494.7 | ||||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 1063.16 | 1138.1 | 1355.9 | 1526 | ||||||||||||||||||
cash-flows.row.other-investing-activites | -229.98 | 0 | 3.8 | 0 | ||||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | -642.34 | -589.7 | -334.5 | -2155.4 | ||||||||||||||||||
cash-flows.row.debt-repayment | -1492.91 | -201.8 | -637.8 | -341.8 | ||||||||||||||||||
cash-flows.row.common-stock-issued | -250.46 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.common-stock-repurchased | -0.5 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.dividends-paid | -219.61 | -206.7 | -340.5 | -195.5 | ||||||||||||||||||
cash-flows.row.other-financing-activites | 1205.14 | -13.3 | 795.1 | 494.6 | ||||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | -92.13 | -431.9 | -183.2 | -42.8 | ||||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 1.14 | 0.6 | 3 | -0.7 | ||||||||||||||||||
cash-flows.row.net-change-in-cash | 215.99 | -34.1 | -229.1 | -1164 | ||||||||||||||||||
cash-flows.row.cash-at-end-of-period | 1573.63 | 403.4 | 437.6 | 666.6 | ||||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 1357.64 | 437.6 | 666.6 | 1830.6 | ||||||||||||||||||
cash-flows.row.operating-cash-flow | 934.39 | 971.9 | 285.7 | 1034.9 | ||||||||||||||||||
cash-flows.row.capital-expenditure | -254.94 | -234.8 | -272.4 | -125.6 | ||||||||||||||||||
cash-flows.row.free-cash-flow | 679.46 | 737.1 | 13.3 | 909.3 |
Pajamų ataskaitos eilutė
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 2101.04 | 2010.3 | 2044.8 | 1770.5 | ||||||||||||||||||
income-statement-row.row.cost-of-revenue | 349.53 | 382.4 | 324.1 | 265.3 | ||||||||||||||||||
income-statement-row.row.gross-profit | 1751.51 | 1627.9 | 1720.6 | 1505.1 | ||||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||||||||||
income-statement-row.row.research-development | 58 | - | - | - | ||||||||||||||||||
income-statement-row.row.selling-general-administrative | 52.87 | - | - | - | ||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 1004.63 | - | - | - | ||||||||||||||||||
income-statement-row.row.other-expenses | -3.15 | 0.8 | 78 | 50.5 | ||||||||||||||||||
income-statement-row.row.operating-expenses | 1191.78 | 1161.6 | 1118.9 | 1007.3 | ||||||||||||||||||
income-statement-row.row.cost-and-expenses | 1541.31 | 1544 | 1443.1 | 1272.6 | ||||||||||||||||||
income-statement-row.row.interest-income | 10.54 | 13.1 | 17 | 34.4 | ||||||||||||||||||
income-statement-row.row.interest-expense | 63.33 | 63.1 | 56.4 | 53.4 | ||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 1004.63 | - | - | - | ||||||||||||||||||
income-statement-row.row.total-other-income-expensenet | 130.43 | 176.2 | -2.3 | -2.3 | ||||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||||||||||
income-statement-row.row.other-operating-expenses | -3.15 | 0.8 | 78 | 50.5 | ||||||||||||||||||
income-statement-row.row.total-operating-expenses | 130.43 | 176.2 | -2.3 | -2.3 | ||||||||||||||||||
income-statement-row.row.interest-expense | 63.33 | 63.1 | 56.4 | 53.4 | ||||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 61.27 | 95.8 | 143.9 | 111 | ||||||||||||||||||
income-statement-row.row.ebitda-caps | 598.17 | - | - | - | ||||||||||||||||||
income-statement-row.row.operating-income | 569.73 | 466.3 | 521.5 | 790.2 | ||||||||||||||||||
income-statement-row.row.income-before-tax | 672.15 | 642.5 | 519.2 | 787.9 | ||||||||||||||||||
income-statement-row.row.income-tax-expense | 73.04 | 65.2 | 49.7 | 77.1 | ||||||||||||||||||
income-statement-row.row.net-income | 585.9 | 581.2 | 472.5 | 715.9 |
Dažnai užduodami klausimai
Kas yra Tibet Cheezheng Tibetan Medicine Co., Ltd. (002287.SZ) bendras turtas?
Tibet Cheezheng Tibetan Medicine Co., Ltd. (002287.SZ) bendras turtas yra 6298478593.000.
Kokios yra įmonės metinės pajamos?
Metinės pajamos yra 1150739074.000.
Kokia yra įmonės pelno marža?
Įmonės pelno marža yra 0.834.
Koks yra įmonės laisvųjų pinigų srautas?
Laisvųjų pinigų srautas yra 1.281.
Kokia yra įmonės grynojo pelno marža?
Grynojo pelno marža yra 0.279.
Kokios yra bendros įmonės pajamos?
Bendrosios pajamos yra 0.271.
Kas yra Tibet Cheezheng Tibetan Medicine Co., Ltd. (002287.SZ) grynasis pelnas (grynosios pajamos)?
Grynasis pelnas (grynosios pajamos) yra 581198850.000.
Kokia yra bendra įmonės skola?
Bendra skola yra 1546314759.000.
Koks yra veiklos sąnaudų skaičius?
Veiklos sąnaudos yra 1161615874.000.
Koks yra įmonės grynųjų pinigų skaičius?
Įmonės grynieji pinigai yra 357241866.000.